AU2023204433A1 - Deuterated organic compounds and uses thereof - Google Patents

Deuterated organic compounds and uses thereof Download PDF

Info

Publication number
AU2023204433A1
AU2023204433A1 AU2023204433A AU2023204433A AU2023204433A1 AU 2023204433 A1 AU2023204433 A1 AU 2023204433A1 AU 2023204433 A AU2023204433 A AU 2023204433A AU 2023204433 A AU2023204433 A AU 2023204433A AU 2023204433 A1 AU2023204433 A1 AU 2023204433A1
Authority
AU
Australia
Prior art keywords
compound
disorder
formula
free
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023204433A
Other languages
English (en)
Inventor
David Garvey
Jordi SERRATS
Vikram SUDARSAN
Krishna VADODARIA
Kimberly Vanover
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Engrail Therapeutics Inc
Original Assignee
Engrail Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engrail Therapeutics Inc filed Critical Engrail Therapeutics Inc
Publication of AU2023204433A1 publication Critical patent/AU2023204433A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2023204433A 2022-01-03 2023-01-03 Deuterated organic compounds and uses thereof Pending AU2023204433A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202263296137P 2022-01-03 2022-01-03
US63/296,137 2022-01-03
US202263314466P 2022-02-27 2022-02-27
US63/314,466 2022-02-27
US202263345002P 2022-05-23 2022-05-23
US63/345,002 2022-05-23
US202263394565P 2022-08-02 2022-08-02
US63/394,565 2022-08-02
US202263384988P 2022-11-25 2022-11-25
US63/384,988 2022-11-25
PCT/US2023/010055 WO2023130119A1 (en) 2022-01-03 2023-01-03 Deuterated organic compounds and uses thereof

Publications (1)

Publication Number Publication Date
AU2023204433A1 true AU2023204433A1 (en) 2024-07-18

Family

ID=87000385

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023204433A Pending AU2023204433A1 (en) 2022-01-03 2023-01-03 Deuterated organic compounds and uses thereof

Country Status (10)

Country Link
US (1) US12606523B2 (https=)
EP (1) EP4460292A4 (https=)
JP (1) JP2025501411A (https=)
KR (1) KR20240132477A (https=)
AU (1) AU2023204433A1 (https=)
CA (1) CA3242755A1 (https=)
IL (1) IL313999A (https=)
MX (1) MX2024008371A (https=)
TW (1) TW202333671A (https=)
WO (1) WO2023130119A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202517609A (zh) 2023-07-02 2025-05-01 美商英格瑞治療公司 氘化有機化合物及其用途(二)
WO2026011157A1 (en) 2024-07-05 2026-01-08 Engrail Therapeutics, Inc. Crystalline forms

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4197243A (en) * 1975-04-02 1980-04-08 Yamanouchi Pharmaceutical Co., Ltd. N-1-Benzyl-3-pyrrolidinyl-4-dimethylamino benzamide derivatives
US4210660A (en) 1978-12-20 1980-07-01 Yamanouchi Pharmaceutical Co., Ltd. Benzamide derivatives
TW212139B (https=) 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
SK281042B6 (sk) 1992-09-18 2000-11-07 Yamanouchi Pharmaceutical Co., Ltd Prípravok hydrogélového typu s ustáleným uvoľňovaním
EP0667867A1 (en) 1992-11-05 1995-08-23 Smithkline Beecham Plc Piperidine derivatives as 5-ht4 receptor antagonists
US6872405B2 (en) 2001-05-10 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
KR102373288B1 (ko) 2013-12-03 2022-03-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
CN104744333A (zh) 2013-12-26 2015-07-01 张云 一种奈莫必利的生产方法
US20190343827A1 (en) 2018-05-08 2019-11-14 Izumi Technology, Llc Deuterated analogs of tariquidar
MX2021010198A (es) 2019-02-27 2021-09-21 Univ California Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales.
US20210017160A1 (en) 2019-07-16 2021-01-21 Cyclerion Therapeutics, Inc. DEUTERATED sGC STIMULATORS
TW202340145A (zh) 2022-01-03 2023-10-16 美商恩格瑞爾療法公司 氘化有機化合物及其用途
TW202517609A (zh) 2023-07-02 2025-05-01 美商英格瑞治療公司 氘化有機化合物及其用途(二)

Also Published As

Publication number Publication date
WO2023130119A1 (en) 2023-07-06
US20250011280A1 (en) 2025-01-09
KR20240132477A (ko) 2024-09-03
EP4460292A1 (en) 2024-11-13
CA3242755A1 (en) 2023-07-06
MX2024008371A (es) 2024-12-06
JP2025501411A (ja) 2025-01-17
IL313999A (en) 2024-08-01
TW202333671A (zh) 2023-09-01
EP4460292A4 (en) 2025-07-16
US12606523B2 (en) 2026-04-21

Similar Documents

Publication Publication Date Title
TWI888599B (zh) 取代哌啶化合物及其用途
US12606523B2 (en) Deuterated organic compounds and uses thereof
CN101784273B (zh) (2s，3r)‑n‑(2‑((3‑吡啶基)甲基)‑1‑氮杂双环[2.2.2]辛‑3‑基)苯并呋喃‑2‑甲酰胺、其新的盐形式和用法
US20190083420A1 (en) Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders
US20260098011A1 (en) Deuterated organic compounds and uses thereof
NO341760B1 (no) 7-[2-[4-(6-fluor-3-metyl-1,2-benzisoksazol-5-yl)-1-piperazinyl]etyl]-2-(1-propynyl)-7Hpyrazolo-[ 4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5-amin, eller et farmasøytisk akseptabelt salt derav, farmasøytiske preparater derav, samt dets anvendelse ved behandling av sentralnervesystemsykdommer.
AU2019378907A1 (en) A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (TPH1) for treating diseases or disorders associated with peripheral serotonin
US20250091990A1 (en) Deuterated organic compounds and uses thereof
KR20150036081A (ko) 카르바메이트/우레아 유도체
TWI644914B (zh) １，２，４－三唑并［４，３－ａ］吡啶化合物及其作為ＭＧＬＵＲ２受體之正向異位調節劑的用途
KR101800140B1 (ko) 벤조티아졸론 화합물
US8507482B2 (en) Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
CN118804746A (zh) 氘代有机化合物及其用途
CN118804910A (zh) 氘代有机化合物及其用途
TW201245197A (en) Substituted [(5h-pyrrolo[2,1-c][1,4]benzodiazepin-11-yl)piperazin-1-yl]-2,2-dimethylpropanoic acid compounds as dual activity H1 inverse agonists/5-HT2A antagonists
TWI922338B (zh) 取代哌啶化合物及其用途
CN107567451A (zh) 作为用于治疗心血管疾病的可溶性鸟苷酸环化酶（sgc）刺激物的n‑取代的8‑[(2,6‑二氟苄基)氧基]‑2,6‑二甲基咪唑并[1,2‑a]吡嗪‑3‑甲酰胺衍生物
NZ716165B2 (en) 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS